Role of Duloxetine as Adjuvant in Chemotherapy Induced Peripheral Neuropathic Pain-An Update
Journal: Journal of Addiction Medicine and Therapeutic Science (Vol.2, No. 1)Publication Date: 2016-12-26
Authors : Kalpajit Dutta Rakesh Garg;
Page : 010-012
Keywords : ;
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of many anticancer drugs such as platinum compounds, antitubulins (taxanes and vinca alkaloids), bortezomib and thalidomide [1]. CIPN may manifest as sensory symptoms in hands and feet, typically in a “glove and stocking” pattern; pain, numbness, tingling etc; or motor symptoms such as weakness, deficits in the cranial nerve or autonomic neuropathy [2]. Various pharmacological agents have been evaluated for management of CIPN and have been reported to have variable effects.These agents include amitriptyline, nortriptyline, venlafaxine, gabapentin,pregabaline, lamotrigine, gel mixture of baclofen, amitriptyline and ketamine. These agents have shown variable effects for management of CIPN. The studies have observed to have limited success because of insignificant relief in pain and paresthesia or no difference in pain scores with these drugs [3-7] (Table 1).
Other Latest Articles
- Risks of Methadone use as Substitute Therapy for Opioid Addiction during Pregnancy and use of Clonidine as a Plausible Alternative
- Why the Polarizing of Addiction Professionals Regarding Abstinence versus Harm Reduction Therapy is so Absurd
- Fast Treatment of Methamphetamine Related Anxiety and Depressive Disorders: A Novel Approach
- Tramadol Dependency Treatment: A New Approach
- The Effects of Substance Abuse Following Personal Injury: Five Case Studies from a Medico-Legal Context
Last modified: 2018-09-06 14:09:33